



Press release
Stockholm, March 1, 2010

AbSorber strengthens the position on the US market by acquiring Olerup Inc.

AbSorber strengthen its position on the important US market by acquiring NorDiag's share of Olerup Inc. AbSorber buys the company together with SSP Primers and after the transition will AbSorber own 50 percent of Olerup Inc. and SSP Primers 50 percent.

Olerup Inc. is selling the Olerup SSP HLA typing products and AbSorbers transplantation cross match test in the USA. The American market also includes Canada and South America. Olerup Inc. will continue to market and sell NorDiag's product Arrow on the American market. Olerup Inc today has 7 employees but will be increased as a consequence of the plans to further improve the presence in the HLA market.

AbSorber now has now the opportunity to achieve a more rapid and focused organizational growth that will strengthen the position on the American market for the transplantation cross match test XM-ONE[®] as well as the Olerup SSP HLA typing products. The important North American market represents about 40 percent of the global market.

AbSorber is owned by LinkMed.

About LinkMed

LinkMed develops life science companies in collaboration with innovators and other financiers. By contributing management and capital, LinkMed has created a portfolio of thirteen companies, four in drug development and biotechnology and nine in diagnostics and medical technology. LinkMed is listed on the NASDAQ OMX Stockholm Exchange in the Small Cap section (ticker: LMED).

For more information about AbSorber, please contact:

Anders Karlsson, CEO AbSorber: +46 709 180 010
Or visit www.absorber.se

About AbSorber

AbSorber develops products that facilitate more successful transplantations. AbSorber's first product, the transplantation test XM-ONE[®] detects key antibodies responsible for post transplantation rejection reactions. XM-ONE[®] is already CE marked and FDA approved for sales in the EU and U.S.